# Identification and validation of biomarkers associated with lactic acid metabolism in diabetic nephropathy

**Authors:** Hua Guo, Xiaoman Lu, Guilin Fang, Yun Qi, Huili Cui, Xiaojuan Zhang

PMC · DOI: 10.7717/peerj.20761 · 2026-03-03

## TL;DR

This study identifies PTGS2 and NFE2L2 as key biomarkers linked to lactic acid metabolism in diabetic nephropathy, validated through bioinformatics and clinical testing.

## Contribution

The study introduces PTGS2 and NFE2L2 as novel biomarkers for diabetic nephropathy associated with lactic acid metabolism.

## Key findings

- PTGS2 and NFE2L2 showed significantly elevated expression in DN clinical samples.
- Both biomarkers correlated with immune cell infiltration and key signaling pathways like hypoxia and IL2 STAT5.
- Molecular docking confirmed high-affinity drug interactions for NFE2L2 and PTGS2.

## Abstract

Previous studies have demonstrated a close association between diabetic nephropathy (DN) and lactic acid metabolism; however, the underlying mechanisms remain unclear. This study aimed to investigate the role of lactic acid metabolism-related biomarkers in the pathogenesis of DN.

The DN training and validation datasets were obtained from public databases, while lactic acid metabolism-related genes (LRGs) were sourced from the literature. Using a comprehensive bioinformatics approach, we screened for potential biomarkers. Subsequent analyses included nomogram construction, functional enrichment, immune cell infiltration profiling, regulatory network mapping, drug target prediction, and molecular docking to elucidate the biomarkers’ roles in DN pathogenesis. Finally, reverse transcription quantitative polymerase chain reaction (RT-qPCR) was performed to validate biomarker expression levels in clinical samples.

Through a comprehensive analysis of bioinformatics methods, we identified two biomarkers—PTGS2 and NFE2L2—as significant candidates in DN. The nomogram demonstrated robust predictive efficacy, validating their utility. NFE2L2 and PTGS2 were positively correlated with the five signal pathways, such as hypoxia and IL2 STAT5 signaling. Both PTGS2 and NFE2L2 had the highest positive correlation with T follicular helper cells (correlation coefficient (cor) = 0.49, p < 0.01, and cor = 0.54, p < 0.01). Two biomarkers predicted multiple miRNAs and transcription factors (TFs), such as miR-144-3p, GATA2, and GATA3. Drug-target analysis highlighted high-affinity interactions for NFE2L2 -lagascatriol and PTGS2 -cimicoxib, further supported by molecular docking. Finally, RT-qPCR confirmed significantly elevated expression of PTGS2 and NFE2L2 in DN samples compared to controls (p < 0.05), aligning with bioinformatics predictions.

## Linked entities

- **Genes:** PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743], NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780], GATA2 (GATA binding protein 2) [NCBI Gene 2624], GATA3 (GATA binding protein 3) [NCBI Gene 2625]
- **Chemicals:** lagascatriol (PubChem CID 10448831), cimicoxib (PubChem CID 213053)
- **Diseases:** diabetic nephropathy (MONDO:0005016)

## Full-text entities

- **Genes:** CCL20 (C-C motif chemokine ligand 20) [NCBI Gene 6364] {aka CKb4, Exodus, LARC, MIP-3-alpha, MIP-3a, MIP3A}, CD40LG (CD40 ligand) [NCBI Gene 959] {aka CD154, CD40L, HIGM1, IGM, IMD3, T-BAM}, TBXAS1 (thromboxane A synthase 1) [NCBI Gene 6916] {aka BDPLT14, CYP5, CYP5A1, GHOSAL, THAS, TS}, Nfe2l2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 83619], HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, NXF1 (nuclear RNA export factor 1) [NCBI Gene 10482] {aka MEX67, TAP}, REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, HGF (hepatocyte growth factor) [NCBI Gene 3082] {aka DFNB39, F-TCF, HGFB, HPTA, SF}, TGFBR1 (transforming growth factor beta receptor 1) [NCBI Gene 7046] {aka AAT5, ACVRLK4, ALK-5, ALK5, ESS1, LDS1}, CTCF (CCCTC-binding factor) [NCBI Gene 10664] {aka CFAP108, FAP108, MRD21}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, CCN2 (cellular communication network factor 2) [NCBI Gene 1490] {aka CTGF, HCS24, IBP-8, IGFBP8, KMD, NOV2}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, MAFK (MAF bZIP transcription factor K) [NCBI Gene 7975] {aka NFE2U, P18}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, MMP1 (matrix metallopeptidase 1) [NCBI Gene 4312] {aka CLG}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, TLR9 (toll like receptor 9) [NCBI Gene 54106] {aka CD289}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, IL15 (interleukin 15) [NCBI Gene 3600] {aka IL-15}, ICAM1 (intercellular adhesion molecule 1) [NCBI Gene 3383] {aka BB2, CD54, P3.58}, SNAI1 (snail family transcriptional repressor 1) [NCBI Gene 6615] {aka SLUGH2, SNA, SNAH, SNAIL, SNAIL1, dJ710H13.1}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, STAT5A (signal transducer and activator of transcription 5A) [NCBI Gene 6776] {aka MGF, STAT5}, E2F1 (E2F transcription factor 1) [NCBI Gene 1869] {aka E2F-1, RBAP1, RBBP3, RBP3}, MMP13 (matrix metallopeptidase 13) [NCBI Gene 4322] {aka CLG3, MANDP1, MDST, MMP-13}, DEFA3 (defensin alpha 3) [NCBI Gene 1668] {aka DEF3, HNP-3, HNP3, HP-3, HP3}, SOX2 (SRY-box transcription factor 2) [NCBI Gene 6657] {aka ANOP3, MCOPS3}, CCR2 (C-C motif chemokine receptor 2) [NCBI Gene 729230] {aka CC-CKR-2, CCR-2, CCR2A, CCR2B, CD192, CKR2}, KEAP1 (kelch like ECH associated protein 1) [NCBI Gene 9817] {aka INrf2, KLHL19}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, GATA3 (GATA binding protein 3) [NCBI Gene 2625] {aka HDR, HDRS}, IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, CXCL3 (C-X-C motif chemokine ligand 3) [NCBI Gene 2921] {aka CINC-2b, GRO3, GROg, MIP-2b, MIP2B, SCYB3}, GATA2 (GATA binding protein 2) [NCBI Gene 2624] {aka DCML, IMD21, MONOMAC, NFE1B}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, PTGS1 (prostaglandin-endoperoxide synthase 1) [NCBI Gene 5742] {aka COX1, COX3, PCOX1, PES-1, PGG/HS, PGHS-1}
- **Diseases:** immune dysregulation (OMIM:614878), malaria (MESH:D008288), DN (MESH:D003928), major depression (MESH:D003865), polycystic kidney disease (MESH:D007690), ketoacidosis (MESH:D007662), Primary immunodeficiency (MESH:D000081207), non (MESH:C580335), hypoxia (MESH:D000860), systemic diseases (MESH:D034721), type 1 or type 2 diabetes (MESH:D003924), autoimmune reactions (MESH:D001327), depression (MESH:D003866), glomerular damage (MESH:D007674), liver dysfunction (MESH:D017093), infection (MESH:D007239), cardiovascular and cerebrovascular diseases (MESH:D002318), Diabetes (MESH:D003920), immune dysfunction (MESH:D007154), ESRD (MESH:D007676), microangiopathy (MESH:D014652), cancer (MESH:D009369), schizophrenia (MESH:D012559), insulin deficiency/resistance (MESH:D007333), primary glomerulonephritis (MESH:D005921), inflammation (MESH:D007249), fibrosis (MESH:D005355), rheumatoid arthritis (MESH:D001172), Hyperglycemia (MESH:D006943), albuminuria (MESH:D000419), hyperosmolar (MESH:D006944), immune impairment (MESH:D020274), Antibody deficiency (MESH:D007153), mitochondrial dysfunction (MESH:D028361)
- **Chemicals:** isopropanol (MESH:D019840), Hydrogen (MESH:D006859), glucose (MESH:D005947), ethanol (MESH:D000431), CIMICOXIB (MESH:C493522), ROS (MESH:D017382), ATP (MESH:D000255), water (MESH:D014867), SYBR Green (MESH:C098022), chloroform (MESH:D002725), lipid (MESH:D008055), TRIzol (MESH:C411644), PGE2 (MESH:D015232), PGE (MESH:D011458), lactate (MESH:D019344), prostaglandin (MESH:D011453), Cl- (MESH:D002713), fatty acid (MESH:D005227), PBS (-), LAGASCATRIOL (MESH:C577706), icosanoid (MESH:D015777), bile acid (MESH:D001647), unsaturated fatty acid (MESH:D005231), Na+ (MESH:D012964), asiatic acid (MESH:C017032)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]

## Figures

12 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12965171/full.md

---
Source: https://tomesphere.com/paper/PMC12965171